Department of Medical Oncology, National Cancer Centre, Singapore.
J Thorac Imaging. 2010 May;25(2):142-50. doi: 10.1097/RTI.0b013e3181d29ccf.
Manipulation of tumor vasculature has emerged as a promising therapeutic strategy in advanced non-small cell lung cancer (NSCLC). Bevacizumab has been licensed for first-line therapy in combination with standard chemotherapy in advanced NSCLC, whereas inhibitors of platelet-derived growth factor receptors and other tyrosine kinases are currently in clinical trials for the treatment of advanced NSCLC. Perfusion computed tomography is a promising biomarker in NSCLC. As a measure of tumor perfusion and angiogenesis, perfusion computed tomography may provide invaluable pharmacodynamic information in early-phase clinical trials, monitor the vascular effects of antiangiogenic or vascular-targeting drug treatment, and provide prognostic and predictive information. Current volumetric techniques, affording a coverage of up to 28 cm, permit clinically relevant, high-quality, whole tumor evaluation.
在晚期非小细胞肺癌（NSCLC）中，肿瘤血管操纵已经成为一种很有前途的治疗策略。贝伐单抗已被批准与标准化疗联合用于晚期 NSCLC 的一线治疗，而血小板衍生生长因子受体抑制剂和其他酪氨酸激酶抑制剂目前正在临床试验中，用于治疗晚期 NSCLC。灌注 CT 是 NSCLC 的一种很有前途的生物标志物。作为肿瘤灌注和血管生成的测量方法，灌注 CT 可能在早期临床试验中提供非常有价值的药效学信息，监测抗血管生成或血管靶向药物治疗的血管效应，并提供预后和预测信息。目前的容积技术可提供高达 28 厘米的覆盖范围，从而实现了对整个肿瘤进行有临床意义的高质量评估。
